THE PROGNOSTIC INFLUENCE OF NEUROENDOCRINE CELLS IN PROSTATE-CANCER - RESULTS OF A LONG-TERM FOLLOW-UP-STUDY WITH PATIENTS TREATED BY RADICAL PROSTATECTOMY

被引:100
作者
NOORDZIJ, MA
VANDERKWAST, TH
VANSTEENBRUGGE, GJ
HOP, WJC
SCHRODER, FH
机构
[1] ERASMUS UNIV ROTTERDAM,DEPT PATHOL,3000 DR ROTTERDAM,NETHERLANDS
[2] ERASMUS UNIV ROTTERDAM,DEPT BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS
[3] ACAD HOSP,ROTTERDAM,NETHERLANDS
关键词
D O I
10.1002/ijc.2910620304
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The distribution of immunohistochemically defined neuroendocrine (NE) cells in benign, pre-cancerous and neoplastic prostatic tissues and the prognostic value of these cells in prostate cancer were studied in the radical prostatectomy specimens of 90 patients from whom complete long-term follow-up data were available. The tissue blocks containing all the different Gleason patterns observed in a particular tumor were selected and immunostained. Since chromogranin B stained only a few cells compared to chromogranin A (CgA), NE cells were only defined by their reactivity with CgA. A semi-quantificative CgA score was assessed for all distinct pathological areas. Cox's regression model was used to analyze the influence of final TNM classification (TNM, 1992), Gleason sum score (GSS), age and CgA score on the probability of progression and tumor-specific death. NE cells were demonstrated in all normal prostatic tissues and in most hyperplastic and intra-epithelial neoplastic lesions. CgA staining was seen in 78% of the tumors. CgA scores were not related with Gleason growth patterns, CSS or TNM classification and had no prognostic value. The independent prognostic variables in Cox's regression model were: CSS and pT stage for progression and GSS for tumor-specific survival. Theoretically, NE cells could influence tumor behavior and this discrepancy suggests the need for experimental studies to investigate the role of NE cells in the normal and neoplastic prostate. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:252 / 258
页数:7
相关论文
共 28 条
[1]   PEPTIDE-HORMONE AND SEROTONIN-IMMUNOREACTIVE CELLS IN NORMAL AND HYPERPLASTIC PROSTATE-GLANDS [J].
ABRAHAMSSON, PA ;
WADSTROM, LB ;
ALUMETS, J ;
FALKMER, S ;
GRIMELIUS, L .
PATHOLOGY RESEARCH AND PRACTICE, 1986, 181 (06) :675-683
[2]   THE COURSE OF NEURO-ENDOCRINE DIFFERENTIATION IN PROSTATIC CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY TESTING CHROMOGRANIN-A AS AN ENDOCRINE MARKER [J].
ABRAHAMSSON, PA ;
FALKMER, S ;
FALT, K ;
GRIMELIUS, L .
PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (03) :373-380
[3]  
AGNESE PAD, 1985, ARCH PATHOL LAB MED, V109, P607
[4]  
AGNESE PAD, 1992, CANCER, V70, P254
[5]   NEUROENDOCRINE DIFFERENTIATION IN METASTATIC PROSTATIC ADENOCARCINOMA [J].
APRIKIAN, AG ;
CORDONCARDO, C ;
FAIR, WR ;
ZHANG, ZF ;
BAZINET, M ;
HAMDY, SM ;
REUTER, VE .
JOURNAL OF UROLOGY, 1994, 151 (04) :914-919
[6]  
APRIKIAN AG, 1993, CANCER, V71, P3952, DOI 10.1002/1097-0142(19930615)71:12<3952::AID-CNCR2820711226>3.0.CO
[7]  
2-X
[8]  
BONO AV, 1985, EUR UROL, V11, P195
[9]  
BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO
[10]  
2-I